Abstract
Respiratory syncytial virus (RSV) hospitalization rates have increased since the American Academy of Pediatrics updated guidelines in 2014 to recommend against the use of palivizumab for preterm infants 29 – 35 weeks’ gestational age (GA) without additional risk factors. A new treatment candidate, nirsevimab, is being developed to target this population. We compared the cost-effectiveness of palivizumab with standard care (no prophylaxis) in this population and estimated the cost-effective price for nirsevimab.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
